CoChat

Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial

Open access
Snider, Cynthia J, Zaman, Khalequ, Estivariz, Concepcion F, Yunus, Mohammad, Weldon, William C, Wannemuehler, Kathleen A, Oberste, M Steven, Pallansch, Mark A, Wassilak, Steven GF, Bari, Tajul Islam A, Anand, Abhijeet · 2019 · The Lancet
Cited by 38

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background Intradermal administration of fractional inactivated poliovirus vaccine (fIPV) is a dose-sparing alternative to intramuscular full dose. We assessed the recommendation of two fIPV doses or one IPV dose for routine immunization, and a fIPV booster dose for outbreak response. Methods We conducted an open-label, randomized, controlled, inequality, non-inferiority trial in two Dhaka clinics, Bangladesh. Healthy infants were randomized at 6 weeks to one of four arms: (A) IPV at 14 weeks and IPV at 22 weeks (booster); (B) IPV at 14 weeks and fIPV booster; (C) IPV at 6 weeks and fIPV booster; or (D) fIPV at 6+14 weeks and fIPV booster. Vaccines were administered by needle-syringe, with intradermal adapter for fIPV. Vaccine response (seroconversion from seronegative (<1:8) at baseline to seropositive (≥1:8) or four-fold increase in reciprocal antibody titers adjusted for maternal antibody decay) to types 1, 2, and 3 at 22 weeks (routine immunization) and 26 weeks (outbreak response) was assessed in the intention-to-treat population. Non-inferiority margin was 12·5%. (Registered at ClinicalTrials.gov, number NCT02847026). Findings From September 1, 2016 to May 2, 2017, 1,076 participants were assigned to Arms A (n=271), B (n=267), C (n=268), and D (n=270). Vaccine response at 22 weeks to two doses of fIPV was significantly higher (p<0.0001) than one dose of IPV (Arm D versus A/B) for type 1 [212 (79%, 95%CI: 73%−83%) versus 305 (57%, 95%CI: 53%−61%)], type 2 [173 (64%, 95%CI: 58%−70%) versus 249 (46%, 95%CI: 42%−51%)], and type 3 [196 (73%, 95%CI: 67%−78%) versus 196 (36%, 95%CI: 33%−41%)]. At 26 weeks, fIPV booster was non-inferior to IPV (Arm B versus A) to types 1 (−1·1%, 90%CI: −2·2% - −0·1%), type 2 (0·4%, 90%CI: −2·2% - 1·4%), and type 3 (−1·5%, 90%CI: −3·2% - −0·2%). Of 129 adverse events, 21 were serious including one death; none were attributed to IPV/fIPV. Interpretation fIPV is an effective dose-sparing strategy for routine immunization and outbreak response. Funding U.S. Centers for Disease Control and Prevention

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(19)30503-3

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 38

Metadata

Authors
Snider, C. J., Zaman, K., Estivariz, C. F., Yunus, M., Weldon, W. C., Wannemuehler, K. A., Oberste, M. S., Pallansch, M. A., Wassilak, S. G., Bari, T. I. A., & Anand, A.
Venue
The Lancet
Publisher
Elsevier BV
Published
2019-06
Volume
393
Issue
10191
Pages
2624-2634
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2945450369
Cited by
38
References
3
FWCI
3.26
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(19)30503-3
The paper
Snider, C. J., Zaman, K., Estivariz, C. F., Yunus, M., Weldon, W. C., Wannemuehler, K. A., Oberste, M. S., Pallansch, M. A., Wassilak, S. G., Bari, T. I. A., & Anand, A. (2019). Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(19)30503-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.